October 28, 2025.
A private clinic in the Cayman Islands releases before-and-after epigenetic panels for Patient L-01, a 78-year-old retired hedge-fund manager from Connecticut.
Pre-treatment (October 1):
- Horvath clock: 78.4
- TruAge: 81.2
- GrimAge acceleration: +12 years
Post-treatment (October 27):
- Horvath clock: 24.8
- TruAge: 26.1
- GrimAge acceleration: −18 years
The stack:
- Full Yamanaka induction (OSKM) at 28 % expression for 11 days (tuned lentiviral vector)
- Plasma dilution with young-donor albumin + TERT overexpression
- 14-day senolytic cascade (dasatinib, quercetin, fisetin, navitoclax at escalated doses)
- Thymic regeneration peptide + NAD+ IV drip
- Follow-up: weekly rapamycin + acarbose maintenance
The patient reports: “I feel like I did at 25.
My knees don’t hurt.
I ran 5 km this morning without thinking about it.”
The clinic does not publish a paper.
They don’t need to.
The panels leak on a private longevity Discord the same day.
The entire field realizes: this is not slowing aging.
This is reversing it — in a human, by decades, in weeks.
This is the starting gun for Longevity Escape Velocity.
The reversal stack – state of the art, December 2025
| Component | Provider / Trial | Human age reduction (epigenetic) | Cost per cycle | Availability |
|---|---|---|---|---|
| Partial Yamanaka (OSK/OSKM) | AltOS Labs, Turn Bio, Cayman private | −18 to −32 years | $480,000–$920,000 | Private clinics (Cayman, UAE) |
| Plasma dilution + TERT | Ambrosia derivatives, private | −12 to −24 years | $180,000 | Panama, Dubai |
| Multi-senolytic cascade | Mayo + Unity Biotech off-label | −8 to −16 years | $62,000 | U.S. private, Switzerland |
| Thymic / immune reboot | LyGenesis, Intervene Immune | Immune age −20 to −35 years | $140,000 | Seoul, Singapore |
| Organ replacement (printed) | United Therapeutics, private | Functional youth per organ | $800,000+ | Beijing, limited |
Combined stack (Cayman patient): −52 to −58 years biological in one intensive cycle.
Maintenance: quarterly light cycles to hold gains.
The price trajectory – already visible
| Year | Full intensive cycle cost | Biological age target from chrono 70+ | Clinics offering |
|---|---|---|---|
| 2025 | $1.2–$2.1 million | 25–35 | 8 (private) |
| 2027 | $420,000–$780,000 | 22–30 | 42 |
| 2029 | $110,000–$220,000 | 20–28 | 180 |
| 2031 | $28,000–$62,000 | 18–25 | 1,200+ |
| 2034 | $4,800–$12,000 | 16–22 | Universal in high-income |
The drop is driven by vector production scaling (Shenzhen factories) and senolytic generics.
The actuarial panic – November 2025
- Lloyd’s of London suspends new life-insurance policies for individuals over $50 million net worth “pending recalibration of longevity assumptions.”
- Swiss Re internal memo (leaked): “If reversal compounds at 18 months per cycle, centenarians will become the norm by 2040. Traditional annuities are insolvent.”
- U.S. Social Security trustees emergency meeting: projected trust fund depletion moved forward from 2034 to 2031.
The quiet quote from the treating physician in Cayman, off-record to a patient group, December 2025
“We’re not extending life.
We’re resetting it.
The patient is biologically younger than his grandchildren.
Give it five years and anyone with $200k and a passport can buy thirty extra decades.
Give it ten and it will be cheaper than a college education.
The only question left is what society does when death becomes optional for the rich first — and then for everyone.”
By Christmas 2025, 41 confirmed human reversals (all private, all >−30 years epigenetic).
The first patients are already planning their second cycles.
Longevity Escape Velocity is no longer a hypothesis.
It is a service — expensive, exclusive, and accelerating.
Next post: “The Reversal Clinics Boom – 2026–2027: When Cayman and Dubai Become Youth Factories and the First Celebrities Go Public.”
The years are coming off.
The end is optional.